7 drugs were approved for clinical use in one day, and 5 were oncology drugs

(People's Daily Health Client Kong Tianjiao) On March 18, the People's Daily Health Client found from the implied permission column for clinical trials and the announcement on the company's official website released by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration on the 17th that many A total of 7 drugs have been approved for clinical use, among which, Beiheng Bio-CTA101UCAR-T cell injection was approved for clinical use, Chia Tai Tianqing TQB3820 tablets were approved for clinical trials, and AstraZeneca's Monalizumab and Oleclumab Injection were approved

Among these clinically approved related drugs, 5 of them are anti-tumor drugs, and the other two are related to the treatment of pneumoconiosis and nephropathy

5 oncology drugs approved for clinical use

On March 17, the official website of the Drug Evaluation Center of the State Food and Drug Administration showed that Chia Tai Tianqing TQB3820 tablets obtained the implied license for clinical trials

According to CDE, the recombinant human anti-PD-L1 and anti-TIGIT bispecific antibody injection HLX301 independently developed by Henlius has been approved by the State Food and Drug Administration to conduct Phase 1 clinical research in China, and is intended to be used for the treatment of advanced tumors

CDE shows that AstraZeneca's Monalizumab and Oleclumab Injection have been approved for clinical use.

Drugs for the treatment of pulmonary tuberculosis, pneumoconiosis, and nephropathy are approved for clinical use

In addition, the CDE official website shows that Wanbonde Pharmaceutical's bromhexine hydrochloride solution for inhalation has been approved for clinical use